Affymetrix mRNA profiling of the in vivo tumor samples revealed no significant changes in BCL-2, MCL-1, BCL-XL and BIM mRNA levels after ABT199 treatment (Supplementary Figure S3E). This evidence concerns the gene BCL2 and neoplasm.